Ezequiel Cordova

B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.

Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 03, 2026

Clinical Characteristics and Outcomes of Bloodstream Infections Caused by Metallo-β-Lactamase-Producing Enterobacterales in Argentina: A Subanalysis of the EMBARCAR Prospective Multicenter Cohort Study.

Clinical Characteristics and Outcomes of Bloodstream Infections Caused by Metallo-β-Lactamase-Producing Enterobacterales in Argentina: A Subanalysis of the EMBARCAR Prospective Multicenter Cohort Study.

Journal: Open forum infectious diseases

Published: October 08, 2025

Overcoming barriers, driving progress: Clinical science at IAS 2025.

Overcoming barriers, driving progress: Clinical science at IAS 2025.

Journal: Journal of the International AIDS Society

Published: October 01, 2025

Efficacy of dolutegravir plus lamivudine in treatment-naïve people with HIV with baseline transmitted drug-resistance mutations.

Efficacy of dolutegravir plus lamivudine in treatment-naïve people with HIV with baseline transmitted drug-resistance mutations.

Journal: AIDS (London, England)

Published: September 27, 2025

Efficacy of dolutegravir plus lamivudine in treatment-naïve people with HIV with baseline transmitted drug-resistance mutations.

Efficacy of dolutegravir plus lamivudine in treatment-naïve people with HIV with baseline transmitted drug-resistance mutations.

Journal: AIDS (London, England)

Published: September 27, 2025

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study.

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study.

Journal: EClinicalMedicine

Published: May 21, 2025

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.

Journal: EClinicalMedicine

Published: May 21, 2025

Carbapenem-Resistant Gram-Negative Bacilli Bacteremia in Argentina (EMBARCAR): Findings From a Prospective, Multicenter Cohort Study.

Carbapenem-Resistant Gram-Negative Bacilli Bacteremia in Argentina (EMBARCAR): Findings From a Prospective, Multicenter Cohort Study.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: November 15, 2024

Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial.

Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial.

Journal: The lancet. HIV

Published: June 21, 2024

Comparative analysis of clinical characteristics, evolution and mortality of hospitalized patients with COVID-19 during the first and second wave of the pandemic (ECCOVID Study)

Comparative analysis of clinical characteristics, evolution and mortality of hospitalized patients with COVID-19 during the first and second wave of the pandemic (ECCOVID Study)

Journal: Medicina

Published: August 15, 2023

Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions.

Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 15, 2023

Assessment of the humoral immunity induced by Sputnik V COVID-19 vaccine (Gam-COVID-Vac) in healthcare workers

Assessment of the humoral immunity induced by Sputnik V COVID-19 vaccine (Gam-COVID-Vac) in healthcare workers

Journal: Vacunas

Published: September 06, 2021

Showing 1-12 of 23

Last Updated: 09/26/2026